Top Page
Asahi Kasei
(OTC:3407)
Asahi Kasei (3407) vs. iShares MSCI Japan ETF (EWJ)
Asahi Kasei Business Overview & Revenue Model
Asahi Kasei Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.04T | 2.78T | 2.73T | 2.46T | 2.11T |
| Gross Profit | 958.26B | 815.97B | 773.78B | 769.77B | 680.71B |
| EBITDA | 389.80B | 218.49B | 120.65B | 366.89B | 287.39B |
| Net Income | 135.00B | 43.81B | -91.31B | 161.88B | 79.77B |
Balance Sheet | |||||
| Total Assets | 4.02T | 3.66T | 3.45T | 3.35T | 2.92T |
| Cash, Cash Equivalents and Short-Term Investments | 393.47B | 338.11B | 251.18B | 244.64B | 221.78B |
| Total Debt | 1.20T | 955.56B | 974.75B | 777.22B | 663.78B |
| Total Liabilities | 2.10T | 1.81T | 1.76T | 1.63T | 1.42T |
| Stockholders Equity | 1.86T | 1.81T | 1.66T | 1.69T | 1.47T |
Cash Flow | |||||
| Free Cash Flow | 99.81B | 123.35B | -81.35B | 13.56B | 103.38B |
| Operating Cash Flow | 301.49B | 295.30B | 90.80B | 183.27B | 253.68B |
| Investing Cash Flow | -364.84B | -142.60B | -213.58B | -221.02B | -157.75B |
| Financing Cash Flow | 128.25B | -94.33B | 111.78B | 42.32B | -95.87B |
Asahi Kasei Technical Analysis
Asahi Kasei Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $1.64T | 13.74 | 6.55% | 3.11% | 5.91% | 78.43% | |
61 Neutral | $10.31B | 6.29 | 0.74% | 2.95% | 3.36% | -36.41% | |
| ― | $8.02B | 43.62 | 1.29% | 4.06% | ― | ― | |
| ― | €4.16B | 14.82 | 20.91% | ― | ― | ― | |
| ― | $4.84B | 18.23 | 5.90% | 3.18% | ― | ― | |
| ― | $4.69B | 78.13 | 0.92% | 2.25% | ― | ― | |
| ― | $5.03B | 15.55 | 6.04% | 2.18% | ― | ― |
Asahi Kasei Corporate Events
Asahi Kasei has revised its consolidated performance forecast for the first half of fiscal 2025, showing a decrease in net sales but an increase in operating and ordinary income. The revision is attributed to increased shipments in the healthcare segment and reduced fixed costs in the materials segment, alongside gains from the sale of investment securities, resulting in a significant rise in net income attributable to the parent company.
The most recent analyst rating on (JP:3407) stock is a Hold with a Yen1140.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei Corporation reported an increase in operating income for the first quarter of fiscal 2025, driven by significant growth in its healthcare segment, particularly pharmaceuticals, and strong performance in domestic housing. However, the company experienced a decrease in net income due to losses from discontinuing its MMA business in the materials segment. Despite this, the company has revised its operating and net income forecasts upward for the first half of 2025, with expectations of improved extraordinary income/loss in the second quarter.
The most recent analyst rating on (JP:3407) stock is a Hold with a Yen1140.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei reported its consolidated financial results for the first quarter of fiscal 2025, showing a slight increase in net sales by 0.3% compared to the previous year. However, net income attributable to owners of the parent decreased by 42.2%. The company maintained its forecast for fiscal 2025, with slight adjustments to its Q1-Q2 outlook. Despite the financial fluctuations, Asahi Kasei continues to focus on its strategic goals, including the elimination of five companies from its consolidation scope, which may impact its operational efficiency and market positioning.
The most recent analyst rating on (JP:3407) stock is a Hold with a Yen1140.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei Corp. has decided to discontinue its MMA, CHMA, PMMA resin, and SB latex businesses due to unfavorable economic conditions and structural challenges. The company will also reconfigure its acetonitrile supply framework, closing its refining plant in Kawasaki. This move is part of a broader strategy to improve capital efficiency and focus on growth areas such as ion-exchange membrane process chlor-alkali electrolysis and hydrogen-related businesses. The restructuring will result in an extraordinary loss of approximately ¥25 billion for the fiscal year ending March 31, 2026, but is not expected to alter the company’s financial forecast.
The most recent analyst rating on (JP:3407) stock is a Hold with a Yen1140.00 price target. To see the full list of analyst forecasts on Asahi Kasei stock, see the JP:3407 Stock Forecast page.
Asahi Kasei Corp. announced an increase in its year-end dividend per share to ¥20 for the fiscal year ending March 31, 2025, reflecting a total annual dividend of ¥38 per share. This decision aligns with their medium-term management plan and shareholder returns policy, which aims to maintain or increase dividends based on free cash flow outlooks. The company also forecasts a further increase in dividends to ¥40 per share for the fiscal year ending March 31, 2026, as part of their ongoing commitment to progressive dividends and enhancing shareholder returns.
Asahi Kasei Corporation reported a record high operating income for the first time in six years, driven by growth in its priority business segments such as pharmaceuticals and digital solutions. Despite economic uncertainties and potential risks from U.S. tariff policies, the company aims to continue its growth trajectory while implementing cost reductions. However, net income is expected to decrease due to structural transformations aligned with their current medium-term plan.